QC Kinetix Increases Standard PRP Dosing to 10 Billion Platelets
They'll roll out the 10B platelet dosing across all 176 locations in the USA, along with blood analysis/patient registry to measure the outcome data. Looking forward to hearing about this.
Most of the pain/sports med physicians reading this know QC Kinetix, but to catch anyone else up, they’re a 9-figure publicly traded corporation administering PRP/BMAC etc. in the USA.
There’s some good literature showing that higher dosage = better outcomes, and it seems that QCKinetix has now changed their ways, upping the dosage to 10 billion platelets as their standard at all 176 locations across the country.
Stay updated on Cell & Gene news
Thanks! Your signup has been saved.
QC Kinetix appears to use Apex Biologix and Emcyte for their PRP processing and kits. The company said that the updated protocol doesn’t significantly change the treatment, besides a higher volume of blood drawn, and hopefully improved patient outcomes.
They also appear to be working on their internal data by using DataBiologics’ patient registry and Horiba blood analyzers to assess how well the new move affects outcomes.
“Our goal is to provide the most effective, evidence-based regenerative treatments for our patients. Through extensive clinical experience, we’ve determined that a standardized baseline of 10 billion platelets maximizes healing potential, providing the most consistent and effective outcomes,” said Dr. Mitchell Sheinkop, national medical director, QC Kinetix. “Most importantly, it means our patients can get back to doing what they love – whether that’s playing with their grandchildren, returning to sports and hobbies, or simply moving without pain.”
Similar stories
Novadip Secures €10.4M for Pivotal Phase 3 Bone Repair Cell Therapy Trial
Ernexa Therapeutics Reports Positive Preclinical iPSC-Derived Mesenchymal Stem Cell Study, Advances Oncology Strategy
Consano Bio’s Platelet-Derived Biologic May Ease Chronic Sciatica, New Study, Advancing RCT
Kangstem Biotech’s Stem Cell for Knee Osteoarthritis Phase 2a Reports Significant ResultsEditor’s Picks
Century Therapeutics Reports Sustained Glucose Control With iPSC-Derived Islets in Diabetic Mice, IND Soon
Inside Cellular Intelligence: The Zuck-Backed AI Company That Acquired Novo’s Parkinson’s Cell Therapy
Webinar: Scaling iPSC Therapies Without Scaling VariabilityOn-Demand
Aspen Neuroscience Publishes Preclinical Data on Parkinson’s iPSC-Derived Cell Therapy
